Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5868278 | 0.87 | KMT2A (0.42) | MEN1KMT2AKDM4CCPB1CPB2 | |
| SCHEMBL1485249 | 0.80 | KDM4C (0.42) | MEN1KMT2AKDM4CCPB1CPB2 | |
| SCHEMBL1485300 | 0.80 | KDM4C (0.42) | MEN1KMT2AKDM4CCPB1CPB2 | |
| SCHEMBL8296606 | 0.76 | KMT2A (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL4196206 | 0.74 | MEN1 (0.46) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL8296605 | 0.74 | MEN1 (0.53) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL8296604 | 0.74 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL4191448 | 0.73 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1485194 | 0.73 | MEN1 (0.37) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL4185104 | 0.73 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056934-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| WO-2005009965-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | MEN1 1824/4885KMT2A 2397/4885KDM4C 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.